IMMUNOVANT, INC.
320 West 37th Street
New York, NY 10018
April 8, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: | Immunovant, Inc. | |||
Registration Statement onForm S-1 | ||||
File No. 333-235975 | ||||
Acceleration Request | ||||
Requested Date: | April 9, 2020 | |||
Requested Time: | 5:30 p.m., Eastern Daylight Time |
Ladies and Gentlemen:
The undersigned registrant hereby requests that the staff of the U.S. Securities and Exchange Commission take appropriate action to cause the Registration Statement onForm S-1 (File No. 333-235975) to become effective on April 9, 2020, at 5:30 p.m., Eastern Daylight Time, or as soon as practicable thereafter.
Very truly yours, | ||
Immunovant, Inc. | ||
By: | /s/ Peter Salzmann, M.D. | |
Name: Peter Salzmann, M.D. | ||
Title: Chief Executive Officer |
cc: | Pamela Yanchik Connealy,Immunovant, Inc. |
W. Bradford Middlekauff,Immunovant, Inc.
Frank F. Rahmani,Cooley LLP
John T. McKenna, Cooley LLP
Alison A. Haggerty,Cooley LLP